Findings
========

Alzheimer\'s disease (AD) is a progressive neurodegenerative disorder characterized by the presence of classical lesions in different brain regions of the neocortex and hippocampus \[[@B1]\]. Among these lesions, the amyloid plaques formed by the aggregation of amyloid-β (Aβ) peptides are prominent. The pathogenesis of the disease is complex and is driven by both environmental and genetic factors. Although most of the cases are sporadic with an obscure etiology, some forms of the disease are inherited and several genes are implicated in familial Alzheimer\'s disease (FAD). The understanding of the molecular basis of the disease gained significant knowledge with the observation that mutations in the three genes linked to early-onset autosomal dominant FAD, increase the production of a highly insoluble isoform of Aβ. Together, these observations support the so-called amyloid hypothesis in the pathogenesis of Alzheimer\'s disease \[[@B2],[@B3]\]. Sequential endoproteolysis of the amyloid-β precursor protein (APP) by the aspartic protease β-secretase/BACE1 and by the γ-secretase proteolytic complex leads to the production of Aβ (see Figure [1A](#F1){ref-type="fig"}). In an alternative non-amyloidogenic pathway, APP is endoproteolyzed within the Aβ region by α-secretase to produce the secreted sAPPα fragment (Figure [1A](#F1){ref-type="fig"}) \[[@B4],[@B5]\].

![**APP processing**. (A) Schematic representation of APP processing. APP undergoes two alternative endoproteolytic pathways. In the amyloidogenic pathway, APP is first cleaved by β-secretase (β) to enable the production of the membrane bound C99 fragment. C99 is then cleaved in its intramembranous domain by γ-secretase (γ) to release Aβ. In the non-amyloidogenic pathway, APP is cleaved by α-secretase (α) to generate sAPPα and the membrane bound C83 fragment. Immunogenic regions for the indicated anti-APP antibodies are shown. (B) HEK293 cells stably transfected with Swedish human APP~695~cDNA \[[@B16]\] were incubated in the absence (Control) or presence of γ-secretase inhibitor (L-685,458, Calbiochem, 1 μM for 18 hrs). APP full-length (APP) and C-terminal fragments (C99 and C83) were analyzed by western blotting (WB) as described before \[[@B16]\], using antibodies directed against APP N-terminal domain (22C11, Chemicon) and APP C-terminal domain (R1, provided by Dr. P.D. Mehta, see Ref. \[[@B16]\]), respectively. Secreted sAPPα and Aβ were analyzed by WB using anti-APP~1--17~antibody (6E10, Signet). Wild type and APP-transfected HEK293 cells were grown in DMEM plus 10% FBS, penicillin and streptomycin in 5% CO~2~at 37°C. APP-transfected HEK293 cells were selected and maintained in 5 μg/ml puromycin.](1756-0500-1-38-1){#F1}

Numerous primary and immortalized cell lines have been used to analyze APP processing and Aβ production in *in vitro*cultures. These cell culture systems have proven to be indispensable for the identification of pharmacological and genetic modifiers of APP metabolism prior to *in vivo*studies \[[@B6]-[@B8]\]. It is estimated that 15 to 35% of cell cultures in current use are infected with mycoplasmas \[[@B9]\]. With a diameter of about 0.2 -- 0.4 μm, mycoplasmas are small, slow-growing bacteria that are generally unaffected by the antibiotics used against common bacteria and fungi. They can go undetected for long periods of time as the contaminated cells may grow normally and appear normal by light microscopy. Mycoplasma contaminations can however have negative effects, ranging from inhibition of metabolism and growth to induction of malignant transformation or apoptosis \[[@B10],[@B11]\]. In this study, we show that mycoplasmas can degrade extracellular Aβ. These results indicate that mycoplasma contaminations can introduce an unsuspected source of variability in Aβ level measurements in cultured cells.

Characterization of extracellular Aβ produced by APP-transfected cells
----------------------------------------------------------------------

The APP metabolites, sAPPα and Aβ, are readily detectable in the conditioned medium of HEK293 cells stably transfected with the human APP~695~isoform (Figure [1B](#F1){ref-type="fig"}, first lane). As expected, treatment of these cells with the selective γ-secretase inhibitor, L-685,458, prevented Aβ production and promoted accumulation of the APP intermediate fragments C99 and C83 (Figure [1B](#F1){ref-type="fig"}, second lane).

Degradation of extracellular Aβ by mycoplasma contaminants
----------------------------------------------------------

To first assess the effect of mycoplasmas on the levels of Aβ in cell culture, medium from mycoplasma-positive cells, detected by polymerase-mediated amplification of mycoplasma genomic DNA (Figure [2A](#F2){ref-type="fig"}), was diluted 1:1 with conditioned medium from APP-transfected HEK293 cells. The resulting mixture was then incubated at 37°C for different periods of time. Under these conditions, we observed a robust degradation of Aβ after 1 hr of incubation, while sAPPα levels were not affected (Figure [2B](#F2){ref-type="fig"}, lanes 3--6). Aβ degradation did not occur when fresh medium (Control DMEM) was mixed with Aβ-containing medium (Figure [2B](#F2){ref-type="fig"}, lanes 1 and 2). Importantly, reduction of the contaminant load by a 0.2 μm filtration of the mycoplasma-positive medium prior to incubation, significantly prevented Aβ degradation (Figure [2B](#F2){ref-type="fig"}, lanes 7--10). Together these data strongly indicate that mycoplasmas efficiently degrade Aβ during normal cell culture conditions.

![**Degradation of extracellular Aβ by mycoplasma contaminants**. (A) PCR amplification of mycoplasma genomic DNA was performed with an internal negative control template (Control -), a positive control template of *M. orale*genomic DNA (Control +), or with medium from mycoplasma-positive HEK293 cell cultures (Mycoplasma+ Medium). Assay was carried out according to manufacturer\'s instructions (MycoSensor PCR Assay Kit, Stratagene). The changes in intensity of the internal control amplification are due to competition with the mycoplasma-specific PCR. (B) Medium from mycoplasma-positive cells was centrifuged at 1000 × g for 10 min to pellet the cell debris. Conditioned medium from APP-transfected HEK293 cells was diluted 1:1 with either fresh medium (Control DMEM), or with unfiltered (Mycoplasma+ Medium) or 0.2 μm filtered \[Mycoplasma+ Medium (Filtered)\] medium from mycoplasma-positive cells. The resulting mixtures were incubated at 37°C for the indicated periods of time. sAPPα and Aβ were analyzed by WB, as described in Figure 1B.](1756-0500-1-38-2){#F2}

Mycoplasma contamination prevents Aβ accumulation in APP-transfected cells
--------------------------------------------------------------------------

In order to confirm the detrimental effect of mycoplasma contamination on Aβ accumulation in cell culture, we directly analyzed Aβ levels produced by mycoplasma-positive APP-transfected HEK293 cells. Interestingly, no Aβ was detected in the conditioned medium of the mycoplasma-positive cells (Figure [3A](#F3){ref-type="fig"}, lane 2), while these cells strongly overexpressed APP (Figure [3A](#F3){ref-type="fig"}, upper panel, lanes 1 and 2).

![**Mycoplasma eradication restored Aβ accumulation in APP-transfected cells**. (A) APP (first panel) and Aβ (second panel) levels in wild-type (wt-293) and APP-transfected (APP-293) HEK293 cells were analyzed by WB, as described before. APP-293 cells were cultured for one week in the absence (-MRA) or presence (+MRA) of Mycoplasma Removal Agent (MRA, MP Biomedicals, Inc). Conditioned medium of untreated and treated APP-293 cells was analyzed by PCR for the presence of mycoplasma genomic DNA (lower panel), as described above. Twenty-five picograms of synthetic Aβ1--40 (IBL-America) were loaded as a control (lane 4). (B) Determination of the mycoplasma species by restriction fragment polymorphism analysis of PCR products. The PCR product was digested with six different restriction endonucleases as indicated and separated on an agarose gel. The fragment pattern identifies the contaminant as *M. hyorhinis*. Briefly, a PCR reaction is performed with a mix of 9 primers to cover a range of mycoplasma species, including major contaminants of cell cultures. The 500--520 bp PCR products, depending on the species, are then subjected to several digests with restriction endonucleases to differentiate between 7 mycoplasma species, as previously described \[[@B14]\]. Cells were cultured without antibiotic for several days. 1 ml of supernatant and 1 ml of trypsinized cells were centrifuged for 10 min at 13,000 rpm and DNA was extracted using DNeasy Blood and Tissue Kit (Qiagen). The PCR was carried out in 50 μl containing 0.2 mM of each deoxynucleotide, 0.2 μM of each primer (sequences provided in Ref. \[[@B17]\]), 1.5 mM MgCl~2~. PCR conditions were as follows, 5 min denaturation at 95°, 35 cycles of 30 sec at 95°C, 30 sec annealing at 65°C and 1 min extension at 72°C followed by a final extension for 10 min. 5 μl of the PCR products were used for restriction digests in 20 μl of reaction volume for 3 hrs. The following enzymes were used: Pfl FI (isoschizomer of Asp I), Bam HI, Hae III, Hpa I, BstBI (isoschizomer of Sfu I) and Xba I. Fragments were analyzed on a 1.5% agarose gel.](1756-0500-1-38-3){#F3}

Mycoplasma eradication restored Aβ accumulation in APP-transfected cells
------------------------------------------------------------------------

Successful mycoplasma decontamination can be achieved by treatments with different antibiotics, including quinolones and tetracyclines \[[@B9]\]. Contaminated APP-transfected cells were treated for one week with the quinolone-based antibiotic, MRA (4-oxo-quinolone-3-carboxylic acid derivative). The antibiotic treatment successfully eradicated the mycoplasmas (Figure [3A](#F3){ref-type="fig"}, lower panel), and restored Aβ accumulation in the conditioned medium of the APP-transfected cells (Figure [3A](#F3){ref-type="fig"}, middle panel). *M. hyorhinis*, *M. orale*, *M. arginini*, *M. fermentans*, *M. hominis*and *Acholeplasma laidlawii*represent 90--95% of the contaminants in mycoplasma-positive cells \[[@B12],[@B13]\]. By restriction fragment length polymorphism assay of PCR products amplified from a region of the conserved 16S rDNA gene in mycoplasma species \[[@B14]\], we determined that the APP-transfected cells were contaminated with the *M. hyorhinis*species (Figure [3B](#F3){ref-type="fig"}). Together these results show that mycoplasmas degrade Aβ in cell cultures.

Discussion
==========

Aβ peptides are degraded in cell culture systems and *in vivo*by at least four peptidases from the metallopeptidase family, neprilysin, endothelin-converting enzyme-1 and -2, and insulin-degrading enzyme \[[@B15]\]. Bacteria express numerous proteases with important biological activities, such as degradation of tissue matrix proteins or activation of zymogens through limited proteolysis. The vast majority of the contaminations in mycoplasma-positive cells are due to *M. hyorhinis*, *M. orale*, *M. arginini*, *M. fermentans*, *M. hominis*and *Acholeplasma laidlawii*\[[@B12],[@B13]\]. Partial sequencing of the *M. hominis*genome predicted the expression of at least three metallopeptidases, and *M. penetrans*, a mycoplasma species isolated from human, is predicted to express oligopeptidase O1, a metallopeptidase from the M13 neprilysin family. Here *M. hyorhinis*was identified in the contaminated APP-transfected cell lines. It is conceivable that *M. hyorhinis*also expresses metallopeptidases with homologies with known mammalian metallopeptidases, which degrade Aβ but not large secreted proteins, such as sAPPα. Contamination with mycoplasmas would therefore provide a very efficient peptidase-driven mechanism of Aβ clearance.

In conclusion, we show that (i) mycoplasmas from cell culture contaminations degrade *in vitro*Aβ produced in cell lines, (ii) mycoplasma-positive APP-transfected cells do not accumulate Aβ in the conditioned medium, and (iii) eradication of the mycoplasma contaminant (i.e. *M. hyorhinis*) by treatments with a quinolone-based antibiotic, restored extracellular Aβ accumulation in APP-transfected cells. Together these results demonstrate that mycoplasmas may represent a significant source of variability when comparing extracellular Aβ levels between different cell lines. We therefore recommend assessment of mycoplasma contamination prior to extracellular Aβ level measurements in cultured cells.
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